Table 2.

Prognostic stratification of stage II and III colorectal cancer patients by clinical parameters and the 7-gene expression classifier ColoGuidePro

	Test series				Validation series^a
	Univariate		Multivariate		Univariate		Multivariate
Parameter	HR^b (95% CI)	P^c	HR^b (95% CI)	P^c	HR^b (95% CI)	P^c	HR^b (95% CI)	P^c
Gender (male vs. female)	1.3 (0.5–3.3)	0.5	1.3 (0.5–3.5)	0.6	1.1 (0.6–2.0)	0.8	0.9 (0.5–1.7)	0.8
Age at diagnosis (≥70 vs. <70 y)	0.8 (0.3–1.9)	0.6	0.6 (0.2–2.1)	0.5	0.8 (0.4–1.4)	0.4	1.1 (0.6–2.1)	0.8
Tumor stage (III vs. II)	1.8 (0.7–4.3)	0.2	1.3 (0.4–4.1)	0.7	2.7 (1.4–5.2)	0.002	2.6 (1.3–5.4)	0.009
Tumor location (right vs. left and rectum)	0.3 (0.1–0.9)	0.03	0.4 (0.2–1.2)	0.1	0.8 (0.4–1.4)	0.4	0.8 (0.4–1.4)	0.4
MSI (MSI-high vs. MSI-low and MSS)	0.2 (0.03–1.4)	0.1	0.4 (0.04–3.1)	0.4	NA	NA	NA	NA
Adjuvant chemotherapy (yes vs. no)	1.1 (0.4–3.0)	0.9	0.6 (0.1–2.6)	0.5	1.5 (0.8–2.7)	0.2	0.9 (0.5–1.8)	0.8
ColoGuidePro	2.9 (1.1–7.5)	0.03	3.2 (1.1–9.3)	0.03	3.7 (2.0–6.8)	<0.001	3.1 (1.6–5.8)	0.001

Abbreviations: MSI, microsatellite instability; MSS, microsatellite-stable; NA, not available.

↵^aGEO accession numbers GSE14333 and GSE17538 (n = 215).
↵^bHRs and corresponding 95% CIs from univariate or multivariate Cox proportional hazards analysis as indicated. Event is relapse or death from colorectal cancer within 5 years. Censoring is no event or lost to follow-up within 5 years.
↵^cP values from Wald test of predictive potential.